An Open Label, Dose Exploration, Safety and Tolerability Study of a Subretinal Injection of an OPGx-001 Gene Vector to Participants With LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) With OCncurrent Non-Interventional Follow-Up of Untreated Patients
Latest Information Update: 26 Oct 2026
At a glance
- Drugs OPGx-001 (Primary)
- Indications Leber congenital amaurosis
- Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
- Acronyms LCA5-IRD
- Sponsors Opus Genetics
Most Recent Events
- 16 Oct 2026 According to an Opus Genetics media release, data presented at Retina in Rio 2026 in Rio de Janeiro, Brazil.
- 16 Oct 2026 Results presented in an Opus Genetics Media Release.
- 16 Jun 2026 According to an Opus Genetics media release, pipeline data from this study were presented at a Research and Development (R&D) Science Forum.